Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Sponsor: Yancheng First People's Hospital
Summary
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited. Previous studies by our team have found that methotrexate can activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.
Official title: Safety and Efficacy of Oral Methotrexate Tablets Combined With Immunotherapy During Radiotherapy for Unresectable/Metastatic Solid Tumors: a Single-center, Prospective Study
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2021-11-15
Completion Date
2026-12-31
Last Updated
2024-10-26
Healthy Volunteers
No
Conditions
Interventions
Methotrexate tablets
Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
Anti-PD-1 monoclonal antibody
Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
Radiotherapy
6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
Locations (1)
Yancheng First People's Hospital
Yancheng, Jiangsu, China